Viamet PharmaceuticalsMay 8, 2015 8:49 am
Founded in 2005, Viamet is a North Carolina (U.S.) based drug discovery company focused on the development and commercialisation of novel small molecule drugs that target metalloenzymes via a proprietary platform called Metallophile® Technology. The pipeline is relatively advanced with Viamet announcing the initiation of a Phase 2b clinical trial of its lead asset, VT-1161, for the treatment of recurrent vulvovaginal candidiasis (RVVC) in February 2015 and an additional Phase 2b clinical trial of VT-1161 for the treatment of onychomycosis (OM) commenced in March 2015. The initial therapeutic focus is human fungal infections. In addition, the drug discovery platform has applicability in many other therapeutic areas.
This post was written by source